SAB Biotherapeutics Statistics
Total Valuation
SABS has a market cap or net worth of $16.07 million. The enterprise value is $10.01 million.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, after market close.
Earnings Date | Aug 7, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
SABS has 9.29 million shares outstanding. The number of shares has increased by 41.12% in one year.
Current Share Class | 9.29M |
Shares Outstanding | 9.29M |
Shares Change (YoY) | +41.12% |
Shares Change (QoQ) | +0.00% |
Owned by Insiders (%) | 20.27% |
Owned by Institutions (%) | 13.93% |
Float | 6.44M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 43.69 |
Forward PS | n/a |
PB Ratio | 0.77 |
P/TBV Ratio | 0.75 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 26.49 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.69, with a Debt / Equity ratio of 0.32.
Current Ratio | 1.69 |
Quick Ratio | 1.33 |
Debt / Equity | 0.32 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -135.73 |
Financial Efficiency
Return on equity (ROE) is -92.35% and return on invested capital (ROIC) is -61.14%.
Return on Equity (ROE) | -92.35% |
Return on Assets (ROA) | -48.28% |
Return on Invested Capital (ROIC) | -61.14% |
Return on Capital Employed (ROCE) | -148.57% |
Revenue Per Employee | $5,997 |
Profits Per Employee | -$544,069 |
Employee Count | 63 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.87% in the last 52 weeks. The beta is 0.55, so SABS's price volatility has been lower than the market average.
Beta (5Y) | 0.55 |
52-Week Price Change | -38.87% |
50-Day Moving Average | 1.75 |
200-Day Moving Average | 2.45 |
Relative Strength Index (RSI) | 42.72 |
Average Volume (20 Days) | 17,593 |
Short Selling Information
The latest short interest is 33,813, so 0.36% of the outstanding shares have been sold short.
Short Interest | 33,813 |
Short Previous Month | 36,810 |
Short % of Shares Out | 0.36% |
Short % of Float | 0.53% |
Short Ratio (days to cover) | 0.54 |
Income Statement
In the last 12 months, SABS had revenue of $377,835 and -$34.28 million in losses. Loss per share was -$3.70.
Revenue | 377,835 |
Gross Profit | -29.39M |
Operating Income | -42.29M |
Pretax Income | -40.32M |
Net Income | -34.28M |
EBITDA | -38.71M |
EBIT | -42.29M |
Loss Per Share | -$3.70 |
Full Income Statement Balance Sheet
The company has $12.85 million in cash and $6.78 million in debt, giving a net cash position of $6.07 million or $0.65 per share.
Cash & Cash Equivalents | 12.85M |
Total Debt | 6.78M |
Net Cash | 6.07M |
Net Cash Per Share | $0.65 |
Equity (Book Value) | 21.41M |
Book Value Per Share | 2.30 |
Working Capital | 6.64M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$31.34 million and capital expenditures -$208,188, giving a free cash flow of -$31.55 million.
Operating Cash Flow | -31.34M |
Capital Expenditures | -208,188 |
Free Cash Flow | -31.55M |
FCF Per Share | -$3.40 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | -11,193.25% |
Pretax Margin | -9,071.77% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
SABS does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -41.12% |
Shareholder Yield | -41.12% |
Earnings Yield | -213.23% |
FCF Yield | -196.26% |
Analyst Forecast
The average price target for SABS is $11.80, which is 582.08% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $11.80 |
Price Target Difference | 582.08% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | 93.62% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on January 5, 2024. It was a reverse split with a ratio of 0.1:1.
Last Split Date | Jan 5, 2024 |
Split Type | Reverse |
Split Ratio | 0.1:1 |
Scores
SABS has an Altman Z-Score of -7.2 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -7.2 |
Piotroski F-Score | 1 |